These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

81 related items for PubMed ID: 1020408

  • 1. [The 131I-fibrinogen turnover during activation of blood fibrinolysis].
    Grabowski R, Bielawiec M, Kiersnowska B, Lukjan H, Perzanowski A, Mysliwiec M, Korfel B, Rogowski F.
    Z Gesamte Inn Med; 1976 Dec 15; 31(24):1025-7. PubMed ID: 1020408
    [Abstract] [Full Text] [Related]

  • 2. Prophylaxis of recurrent venous thrombosis with long-term enhancement of fibrinolysis.
    Bielawiec M, Lukjan H, Myśliwiec M, Dabrowski S.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1979 Dec 15; 106(5-6):971-6. PubMed ID: 94894
    [Abstract] [Full Text] [Related]

  • 3. The effect of phenformin plus stanozolol on fibrinolysis, platelet adhesiveness and blood lipids in patients with recurrent venous thrombosis.
    Bielawiec M, Myśliwiec M, Perzanowski A.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1974 Dec 15; 101(3):483-8. PubMed ID: 4139068
    [No Abstract] [Full Text] [Related]

  • 4. Clinical investigations on long-term activation of fibrinolysis by anabolic steroids.
    Bielawiec M, Bodzenta A, Lukjan H, Kiersnowska-Rogowska B, Kłoczko J, Myśliwiec M, Dabrowski S, Tymiński W, Czestochowska E.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986 Dec 15; 113(1-2):223-9. PubMed ID: 2427405
    [Abstract] [Full Text] [Related]

  • 5. Idiopathic recurrent superficial thrombophlebitis: treatment with fibrinolytic enhancement.
    Jarrett PE, Morland M, Browse NL.
    Br Med J; 1977 Apr 09; 1(6066):933-4. PubMed ID: 856391
    [Abstract] [Full Text] [Related]

  • 6. The role of phenformin and ethyloestrenol or stanozolol in the treatment of decreased fibrinolytic states. (Cutaneous vasculitis, Raynaud's disease, Behcet's syndrome, recurrent deep vein thrombosis and post myocardial infarction).
    Menon IS.
    Acta Univ Carol Med Monogr; 1972 Apr 09; 52():19-23. PubMed ID: 4669824
    [No Abstract] [Full Text] [Related]

  • 7. The effect of increasing fibrinolysis in patients with rheumatoid arthritis: a double blind study of stanozolol.
    Belch JJ, Madhok R, McArdle B, McLaughlin K, Kluft C, Forbes CD, Sturrock RD.
    Q J Med; 1986 Jan 09; 58(225):19-27. PubMed ID: 3517926
    [Abstract] [Full Text] [Related]

  • 8. Clinical and laboratory double-blind investigation on effect of fibrinolytic therapy in patients with cutaneous vasculitis.
    Dodman B, Cunliffe WJ, Roberts BE, Sibbald R.
    Br Med J; 1973 Apr 14; 2(5858):82-4. PubMed ID: 4573315
    [Abstract] [Full Text] [Related]

  • 9. Plasma fibrinolytic system and blood pressure in patients with hypertensive cardiovascular disease treated with reserpine and phenformin.
    Worowski K, Prokopowicz J, Gabryelewicz A.
    Haematologia (Budap); 1970 Apr 14; 4(3):399-403. PubMed ID: 4256949
    [No Abstract] [Full Text] [Related]

  • 10. The effects of phenphormin on blood fibrinolysis in diabetes mellitus.
    Fiaschi E, Barbui T, Previato G, Di Luzio V, Guarnieri GF, Todesco S.
    Arzneimittelforschung; 1969 Apr 14; 19(4):638-40. PubMed ID: 5819165
    [No Abstract] [Full Text] [Related]

  • 11. The effect of combined treatment with phenformin and stanazolol on blood lipids and fibrinolytic activity in patients with hypertriglyceridaemia.
    Ciświcka-Sznajderman M, Berent H, Rymaszewski Z.
    Atherosclerosis; 1974 Apr 14; 19(1):153-9. PubMed ID: 4359182
    [No Abstract] [Full Text] [Related]

  • 12. Plasma beta-thromboglobulin, fibrinopeptide A and B beta 15-42 antigen in relation to postoperative DVT, malignancy and stanozolol treatment.
    Douglas JT, Blamey SL, Lowe GD, Carter DC, Forbes CD.
    Thromb Haemost; 1985 Apr 22; 53(2):235-8. PubMed ID: 2410995
    [Abstract] [Full Text] [Related]

  • 13. Effects of oral stanozolol used in the prevention of postoperative deep vein thrombosis on fibrinolytic activity.
    Sue-Ling HM, Davies JA, Prentice CR, Verheijen JH, Kluft C.
    Thromb Haemost; 1985 Feb 18; 53(1):141-2. PubMed ID: 3873118
    [Abstract] [Full Text] [Related]

  • 14. [Effect of Complamin on fibrinolysis and platelet aggregation in the aged].
    Matijević N, Sisić I, Korolija P, Pendić B.
    Bilt Hematol Transfuz; 1980 Feb 18; 8(1):37-43. PubMed ID: 7337681
    [Abstract] [Full Text] [Related]

  • 15. Comparative effects of platelet adhesiveness by phenformin combined with ethylestrenol or stanozolol.
    Chakrabarti R.
    Acta Univ Carol Med Monogr; 1972 Feb 18; 53():261-2. PubMed ID: 4670736
    [No Abstract] [Full Text] [Related]

  • 16. [Effect of phenformin and stanozol administration on lipid metabolism in patients with occlusive vascular diseases].
    Perzanowski A, Bielawiec M, Myśliwiec M.
    Pol Tyg Lek; 1972 Jan 31; 27(5):174-6. PubMed ID: 5010762
    [No Abstract] [Full Text] [Related]

  • 17. Stanozolol-induced changes in fibrinolysis and coagulation in healthy adults.
    Kluft C, Preston FE, Malia RG, Bertina RM, Wijngaards G, Greaves M, Verheijen JH, Dooijewaard G.
    Thromb Haemost; 1984 Apr 30; 51(2):157-64. PubMed ID: 6740547
    [Abstract] [Full Text] [Related]

  • 18. Fibrinolytic enhancement by stanozolol: a double blind trial.
    Davidson JF, Lochhead M, McDonald GA, McNicol GP.
    Br J Haematol; 1972 May 30; 22(5):543-59. PubMed ID: 4555715
    [No Abstract] [Full Text] [Related]

  • 19. [Effect of complamin on the systemic and cerebral hemodynamics of atherosclerosis patients with chronic cerebral vascular disorders].
    Ishchenko MM, Dorogiĭ AN.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1985 May 30; 85(1):59-65. PubMed ID: 3984595
    [Abstract] [Full Text] [Related]

  • 20. [Effect of complamine, nonachlazine, riboxine and clofeline on the fibrinogen content and fibrinolytic activity of the blood].
    Kremneva VF, Shevchenko LV.
    Farmakol Toksikol; 1980 May 30; 43(3):330-5. PubMed ID: 7449972
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.